Main content

    Liver Transplant / Hepatology / Hepatitis / Liver Failure Clinical Trials

    Liver Disease Management & Transplant Program

    Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Liver Failure including Acute Liver Injury  |  Drug and CAM Induced Liver Injury  |  Co-infection (HCV & HIV)  |  Thrombocytopenia  |  Hepatitis C  |  Hepatoma


    Active Trials

    Liver Failure including Acute Liver Injury

    Title: Multicenter, Randomized Phase 2B Study Evaluating Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Cirrhotic Patients With Associated Hyperammonemia and an Episode of Hepatic Encephalopathy STOP-HE Study
    Decscription: The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients
    Investigator: Todd Frederick, MD
    Eligibility: Subjects, 18 y/o and older, who are hospitalized with an acute episode of hepatic encephalopathy as complication of cirrhosis
    Status: Active and open to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study Ocera STOP-HE

    Back to top

    Drug and CAM Induced Liver Injury


    Currently there are no Clinical Research Studies for Drug and CAM Induced Liver Injury. Please check back at a later date as we are always adding new studies.

    Back to top

    Co-infection (HCV & HIV)

    Title: A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
    Decscription: This is a multicenter, open-label study that will evaluate the antiviral efficacy, safety and tolerability of SOF/LDV FDC administered for 12 weeks in HCV treatment-naive and treatment-experienced (including treatment intolerant) subjects with chronic genotype 1 or 4 HCV infection who are co-infected with HIV-1
    Investigator: Todd Frederick, MD
    Eligibility: Subjects, 18 y/o and older, with HCV genotype 1 or 4 and co-infected with HIV
    Status: Active and open to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study GS-0115

    Back to top

    Thrombocytopenia

    Title: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure
    Decscription: Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
    Investigator: Todd Frederick, MD
    Eligibility: Subjects, 18 y/o and older, with chronic liver disease scheduled to undergo a permitted elective procedure who, in the opinion of the investigator, will require a platelet transfusion to address a risk of bleeding associated with the procedure
    Status: Active and open to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study Eisai 311

    Back to top

    Hepatitis C

    Title: An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ┬▒ Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Study
    Decscription: This is an open label study that will investigate the safety, tolerability and antiviral efficacy of SOF/LDV with or without RBV for 12 or 24 weeks in chronic genotype 1 HCV infected subjects that failed prior treatment in a previous Gilead-sponsored HCV treatment study
    Investigator: Todd Frederick, MD
    Eligibility: Subjects, 18 y/o and older, with HCV genotype 1 who have participated in a previous Gilead-sponsored HCV study
    Status: Active and open to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study GS-1118

    Title: A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection
    Decscription: This study is to assess the safety and efficacy of 16 or 24 weeks of sofosbuvir+ribavirin (RBV), and 12 weeks of sofosbuvir+pegylated interferon alfa-2a (PEG)+RBV in treatment-naive and treatment-experienced adults with chronic genotype 3 hepatitis C virus (HCV) infection, and treatment-experienced adults with cirrhosis and chronic genotype 2 HCV infection
    Investigator: Todd Frederick, MD
    Eligibility: Subjects 18 y/o and older with a confirmed chronic HCV infection
    Status: Closed to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study GS-0153

    Back to top

    Hepatoma

    Please click here to see our Hepatoma clinical trials.


    • updated February 2014

    Back to top